ReviewClinical cardiology2014
Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation.
Review in Clinical cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Pooled it
- Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.Clinical cardiology · 2016Trial
- Discordant Antithrombotic Effects of Apixaban in Fibrillating Left Atria vs Post-Myocardial Infarction Left Ventricular Aneurysm.JACC. Case reports · 2025Article
- Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation.Drugs in context · 2024Article
- Apixaban in Patients With Post-Myocardial Infarction Left Ventricular Thrombus: A Randomized Clinical Trial.CJC open · 2023Article
- Acute Saddle Embolus With Thrombus in Transit: A Case Report and Review of the Literature.Cureus · 2022Article
- Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.Cardiology and therapy · 2022Review
- Novel oral anticoagulants in intracardiac thrombosis resolution: a case series.European heart journal. Case reports · 2020Article
- Use of dabigatran for treatment of left ventricular thrombus: A tertiary care center experience.Journal of family medicine and primary care · 2019Article
- Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment.Cardiology research and practice · 2019Article
- Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature.Clinical case reports · 2019Article
- Left atrial appendage exclusion during mitral valve surgery and stroke in atrial fibrillation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2018Article
- Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice.British journal of clinical pharmacology · 2018Article
- Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era.Therapeutic advances in chronic disease · 2017Review
- Massive Left Atrial Thrombi during Dabigatran Therapy for Nonvalvular Atrial Fibrillation.CASE (Philadelphia, Pa.) · 2017Article
- Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation.Clinical cardiology · 2017Review
- Off label use of direct oral anticoagulants for left ventricular thrombus. Is it appropriate?American journal of cardiovascular disease · 2017Article
- Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.PloS one · 2017Article
- Article
- Individualising Anticoagulant Therapy in Atrial Fibrillation Patients.Arrhythmia & electrophysiology review · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, represent new options for preventing stroke in patients with atrial fibrillation, as shown by the results from large, randomized phase III trials. Because of their greater specificity, rapid onset of action, and predictable pharmacokinetics, the novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) address several limitations of warfarin or other vitamin K antagonists in day-to-day clinical practice. However, a range of practical questions relating to the novel oral anticoagulants has emerged, including topics such as patient selection, treatment of patients with renal impairment, risk of myocardial infarction, drug interactions, switching between anticoagulants, and management of bleeding, in addition to use of these agents in patients requiring antiplatelet drug treatment or undergoing cardioversion or percutaneous interventions (eg, ablation). In this review, practical aspects of the use of novel oral anticoagulants in patients with atrial fibrillation are discussed, with reference to available data and guidance from prescribing information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.